CNS Cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII...

Neuroendocrine Tumors

Health-Related Quality of Life in Everolimus-Treated Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel and colleagues, no significant difference in deterioration of health-related quality of life was observed with everolimus...

Hepatobiliary Cancer

Individualized Adaptive Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors

In a single-center phase II study reported in JAMA Oncology, Feng and colleagues found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control...


Advertisement

More Top Stories

Prostate Cancer

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

Solid Tumors
Breast Cancer

Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer

The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends documented “are remarkable for their steepness of decline, independent of clinical factors and despite no...

Advertisement

U.S. Incidence and Projected Rise of Merkel Cell Carcinoma

The number of U.S. cases of Merkel cell carcinoma is rising about six times faster than most other cancers, and at nearly twice the rate of melanoma. Paulson et al reported these findings in The Journal of the American Academy of Dermatology, which are based on research conducted at the University...

Bladder Cancer

John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial

Genomics/Genetics
Issues in Oncology

Making Personalized Medicine a Reality for More Patients With Cancer

  This past September, Olivier Elemento, PhD, Associate Director of the Institute for Computational Biomedicine and Director of the Laboratory of Cancer Systems Biology at Weill Cornell Medicine in New York, was named Director of Weill Cornell’s Englander Institute for Precision Medicine. In this...

Breast Cancer

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

AS REPORTED BY Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying...

Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis

In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....

Prostate Cancer

Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture

Genomics/Genetics
Issues in Oncology

Making Personalized Medicine a Reality for More Patients With Cancer

  This past September, Olivier Elemento, PhD, Associate Director of the Institute for Computational Biomedicine and Director of the Laboratory of Cancer Systems Biology at Weill Cornell Medicine in New York, was named Director of Weill Cornell’s Englander Institute for Precision Medicine. In this...

Advertisement

Dose Rounding of Anticancer Agents: Hematology/Oncology Pharmacy Association Position Statement

As reported in the Journal of Oncology Practice by Fahrenbruch et al, the Hematology/Oncology Pharmacy Association (HOPA) has issued a position statement on dose rounding of biologic and cytotoxic anticancer agents. To formulate the position statement, the HOPA standards committee organized a work ...